Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful?

PurposePrevious studies indicate a possible inverse relationship between prostate-specific antigen (PSA) and body mass index (BMI), and a positive relationship between PSA and age. We investigated the associations between age, BMI, PSA, and screen-detected prostate cancer to determine whether an age–BMI-adjusted PSA model would be clinically useful for detecting prostate cancer.MethodsCross-sectional analysis nested within the UK ProtecT trial of treatments for localized cancer. Of 18,238 men aged 50–69 years, 9,457 men without screen-detected prostate cancer (controls) and 1,836 men with prostate cancer (cases) met inclusion criteria: no history of prostate cancer or diabetes; PSA < 10 ng/ml; BMI between 15 and 50 kg/m2. Multivariable linear regression models were used to investigate the relationship between log-PSA, age, and BMI in all men, controlling for prostate cancer status.ResultsIn the 11,293 included men, the median PSA was 1.2 ng/ml (IQR: 0.7–2.6); mean age 61.7 years (SD 4.9); and mean BMI 26.8 kg/m2 (SD 3.7). There were a 5.1% decrease in PSA per 5 kg/m2 increase in BMI (95% CI 3.4–6.8) and a 13.6% increase in PSA per 5-year increase in age (95% CI 12.0–15.1). Interaction tests showed no evidence for different associations between age, BMI, and PSA in men above and below 3.0 ng/ml (all p for interaction >0.2). The age–BMI-adjusted PSA model performed as well as an age-adjusted model based on National Institute for Health and Care Excellence (NICE) guidelines at detecting prostate cancer.ConclusionsAge and BMI were associated with small changes in PSA. An age–BMI-adjusted PSA model is no more clinically useful for detecting prostate cancer than current NICE guidelines. Future studies looking at the effect of different variables on PSA, independent of their effect on prostate cancer, may improve the discrimination of PSA for prostate cancer.

[1]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[2]  A. Neugut,et al.  Modeling the effects of obesity and weight gain on PSA velocity , 2009, The Prostate.

[3]  E. Steyerberg,et al.  A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. , 2013, European urology.

[4]  C. Lindsell,et al.  Relationship Between Prostate-specific Antigen, Age, and Body Mass Index in a Prostate Cancer Screening Population , 2012, American journal of clinical oncology.

[5]  Jacques Ferlay,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .

[6]  Prostate Cancer Can Be Detected Even in Patients with Decreased PSA Less than 2.5 ng/ml after Treatment of Chronic Prostatitis , 2011, Korean journal of urology.

[7]  S. Iravani,et al.  Opium Consumption Is Negatively Associated With Serum Prostate-Specific Antigen (PSA), Free PSA, and Percentage of Free PSA Levels , 2013, Journal of addiction medicine.

[8]  A. Qureshi,et al.  Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. , 2012, American journal of epidemiology.

[9]  Q. Mcnemar.  Note on the sampling error of the difference between correlated proportions or percentages , 1947, Psychometrika.

[10]  U B Seiffert,et al.  Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations. , 1996, Clinical chemistry.

[11]  W. Catalona,et al.  Personalized prostate specific antigen testing using genetic variants may reduce unnecessary prostate biopsies. , 2013, The Journal of urology.

[12]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[13]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[14]  V. Master,et al.  Association between smoking status, and free, total and percent free prostate specific antigen. , 2012, The Journal of urology.

[15]  Nicolas Barry Delongchamps,et al.  Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. , 2007, Journal of the National Cancer Institute.

[16]  A. Actis,et al.  Prostate-specific antigen: its relationship with alcohol intake and tobacco , 2012, Medical Oncology.

[17]  R. Hayes,et al.  Cancer Causes & Control , 2004, Cancer Causes & Control.

[18]  F. Hamdy,et al.  Very low PSA concentrations and deletions of the KLK3 gene. , 2013, Clinical chemistry.

[19]  J. Stanford,et al.  The effect of demographic and clinical factors on the relationship between BMI and PSA levels , 2011, The Prostate.

[20]  I. Thompson,et al.  Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. , 2010, Urology.

[21]  T. Peters,et al.  Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. , 2014, The Lancet. Oncology.

[22]  M. Terris,et al.  Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. , 2007, JAMA.

[23]  P. H. Petersen,et al.  Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. , 2005, Clinical chemistry.

[24]  B. Kramer,et al.  Screening for prostate cancer with PSA testing: current status and future directions. , 2011, Oncology.

[25]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[26]  F. Hamdy,et al.  Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[27]  F. Montorsi,et al.  Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study , 2012, BJU international.

[28]  D. Freedman,et al.  Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004 , 2007, Cancer Epidemiology Biomarkers & Prevention.

[29]  H. Brenner,et al.  Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[30]  L. Ferrucci,et al.  Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. , 2009, The Journal of urology.

[31]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[32]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[33]  Xiangyi Zheng,et al.  Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis , 2011, Irish journal of medical science.

[34]  F. Hamdy,et al.  Association of diabetes mellitus with prostate cancer: Nested case–control study (Prostate testing for cancer and Treatment study) , 2011, International journal of cancer.

[35]  S. Culp,et al.  The effect of obesity and lower serum prostate‐specific antigen levels on prostate‐cancer screening results in American men , 2009, BJU international.

[36]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[37]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[38]  Ulleryd,et al.  Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate‐specific antigen and transrectal ultrasonography , 1999, BJU international.

[39]  V. Fontana,et al.  Effect of Age, Family History of Prostate Cancer, Prostate Enlargement and Seasonality on PSA Levels in a Contemporary Cohort of Healthy Italian Subjects , 2011, The International journal of biological markers.

[40]  Lei Xie,et al.  Body mass index and risk of BPH: a meta-analysis , 2011, Prostate Cancer and Prostatic Diseases.

[41]  M. Issa,et al.  Evaluation of novel formula of PSA, age, prostate volume, and race in predicting positive prostate biopsy findings. , 2013, Urology.

[42]  H. Klocker,et al.  Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. , 2011, Urology.

[43]  W. Demark-Wahnefried,et al.  Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. , 2004, Urology.

[44]  Carmen Rodriguez,et al.  Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort , 2007, Cancer Epidemiology Biomarkers & Prevention.

[45]  Xianglin L. Du,et al.  Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. , 2011, Central European journal of public health.

[46]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[47]  F. Hamdy,et al.  Seasonal variation in prostate‐specific antigen levels: a large cross‐sectional study of men in the UK , 2011, BJU international.

[48]  P. Walsh.  The association of body mass index and prostate-specific antigen in a population-based study. , 2005, The Journal of urology.

[49]  N. Hamajima,et al.  ASSOCIATION OF OBESITY AND DIABETES WITH SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS IN JAPANESE MALES , 2012, Nagoya journal of medical science.

[50]  J. Oesterling.  Age-specific reference ranges for serum PSA. , 1996, The New England journal of medicine.

[51]  L. Marignol,et al.  Standardization of assay methods reduces variability of total PSA measurements: an Irish study , 2012, BJU international.